This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
TIRZEPATIDE
$
79 AUD
Product Info
Tirzepatide is a synthetic peptide studied in laboratory research for its dual activity on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is commonly used in controlled experimental settings to investigate metabolic signalling, receptor interaction, and endocrine regulation pathways. Tirzepatide is of interest in studies examining energy balance, insulin signalling, and peptide-based metabolic mechanisms. This compound is supplied strictly for research purposes only and is not intended for human or veterinary use.
Buy 3 and save 15%
Buy 5 and save 20%
Categories
Bacteriostatic Water
AOD
Cagrilintide
Cagrilintide + Semaglutide
Retatrutide
Semaglutide
Tirzepatide
SLU PP 332
MOTS C
BPC 157
bpc-157-tb-500
Description
Overview
Biochemical Characteristics
Research Applications
Pathway / Mechanistic Context
Form & Analytical Testing
RUO Disclaimer
Overview
Biochemical Characteristics
Research Applications
Pathway / Mechanistic Context
Form & Analytical Testing
RUO Disclaimer
Overview
Tirzepatide is a synthetic dual agonist peptide that simultaneously activates GLP-1 and GIP receptors, designed for synergistic metabolic effects in glucose homeostasis and weight management. The peptide targets complementary pathways regulating insulin secretion, glucagon suppression, appetite, and metabolic rate. Tirzepatide is extensively studied for its potential in supporting glucose control, body weight reduction, and metabolic health with enhanced efficacy compared to GLP-1 monotherapy. Research indicates the dual agonist approach provides superior glycemic control, greater weight loss, and improved metabolic parameters through coordinated activation of GLP-1 and GIP receptor systems. Tirzepatide represents a valuable research tool for investigating dual receptor signaling, synergistic metabolic effects, and therapeutic approaches to type 2 diabetes and obesity.
Overview
Tirzepatide is a synthetic dual agonist peptide that simultaneously activates GLP-1 and GIP receptors, designed for synergistic metabolic effects in glucose homeostasis and weight management. The peptide targets complementary pathways regulating insulin secretion, glucagon suppression, appetite, and metabolic rate. Tirzepatide is extensively studied for its potential in supporting glucose control, body weight reduction, and metabolic health with enhanced efficacy compared to GLP-1 monotherapy. Research indicates the dual agonist approach provides superior glycemic control, greater weight loss, and improved metabolic parameters through coordinated activation of GLP-1 and GIP receptor systems. Tirzepatide represents a valuable research tool for investigating dual receptor signaling, synergistic metabolic effects, and therapeutic approaches to type 2 diabetes and obesity.
Biochemical Characteristics
Tirzepatide is a modified peptide engineered to activate both GLP-1 and GIP receptors with balanced dual agonist activity. Molecular weight approximately 4,181 Da. The peptide structure incorporates fatty acid acylation (palmitic acid modification) enabling albumin binding and extended serum half-life. The peptide is water-soluble with stability across physiological pH ranges (6.5–8.0). Tirzepatide demonstrates extended biological half-life due to albumin binding and resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and other peptidases. Cellular uptake occurs through distinct GLP-1 and GIP receptor pathways on pancreatic beta cells, gastrointestinal epithelium, liver, and central nervous system tissues involved in metabolic regulation.
Biochemical Characteristics
Tirzepatide is a modified peptide engineered to activate both GLP-1 and GIP receptors with balanced dual agonist activity. Molecular weight approximately 4,181 Da. The peptide structure incorporates fatty acid acylation (palmitic acid modification) enabling albumin binding and extended serum half-life. The peptide is water-soluble with stability across physiological pH ranges (6.5–8.0). Tirzepatide demonstrates extended biological half-life due to albumin binding and resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and other peptidases. Cellular uptake occurs through distinct GLP-1 and GIP receptor pathways on pancreatic beta cells, gastrointestinal epithelium, liver, and central nervous system tissues involved in metabolic regulation.
Research Applications
Glucose Control Enhancement Investigation of superior glycemic control through dual GLP-1 and GIP receptor activation. Body Weight Reduction Assessment of greater weight loss compared to GLP-1 monotherapy through enhanced appetite suppression and metabolic effects. Type 2 Diabetes Models Study of improved HbA1c levels and metabolic function in diabetes research applications. Insulin Sensitivity Investigation of enhanced peripheral tissue insulin sensitivity and improved metabolic flexibility. Metabolic Syndrome Assessment of improvements in lipid profiles, inflammation markers, and cardiometabolic risk factors. Beta Cell Function Study of preservation of pancreatic beta cell function and prevention of functional decline. Cardiovascular Metabolic Health Investigation of protective effects on cardiometabolic outcomes and vascular function.
Research Applications
Glucose Control Enhancement Investigation of superior glycemic control through dual GLP-1 and GIP receptor activation. Body Weight Reduction Assessment of greater weight loss compared to GLP-1 monotherapy through enhanced appetite suppression and metabolic effects. Type 2 Diabetes Models Study of improved HbA1c levels and metabolic function in diabetes research applications. Insulin Sensitivity Investigation of enhanced peripheral tissue insulin sensitivity and improved metabolic flexibility. Metabolic Syndrome Assessment of improvements in lipid profiles, inflammation markers, and cardiometabolic risk factors. Beta Cell Function Study of preservation of pancreatic beta cell function and prevention of functional decline. Cardiovascular Metabolic Health Investigation of protective effects on cardiometabolic outcomes and vascular function.
Pathway / Mechanistic Context
GLP-1 Receptor Activation Tirzepatide activates GLP-1 receptors on pancreatic beta cells and intestinal L-cells, promoting glucose-dependent insulin secretion and slowing gastric emptying for improved postprandial glucose control. GIP Receptor Signaling The peptide activates GIP receptors on beta cells and adipocytes, enhancing insulin secretion, modulating adipocyte metabolism, and improving glucose-dependent insulinotropic action. Glucagon Suppression Coordinated GLP-1 and GIP activation suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production and supporting glycemic control. Gastric Emptying Slowing GLP-1 receptor activation slows gastric motility and nutrient absorption, reducing meal-stimulated glucose excursions and promoting sustained satiety. Central Appetite Suppression Both GLP-1 and GIP receptors activate hypothalamic appetite suppression pathways, providing synergistic reduction in hunger and food intake through overlapping neural mechanisms. Metabolic Optimization Dual activation of GLP-1 and GIP creates complementary metabolic effects—GLP-1 enhancing insulin secretion and gastric slowing while GIP modulates adipocyte metabolism and metabolic flexibility.
Pathway / Mechanistic Context
GLP-1 Receptor Activation Tirzepatide activates GLP-1 receptors on pancreatic beta cells and intestinal L-cells, promoting glucose-dependent insulin secretion and slowing gastric emptying for improved postprandial glucose control. GIP Receptor Signaling The peptide activates GIP receptors on beta cells and adipocytes, enhancing insulin secretion, modulating adipocyte metabolism, and improving glucose-dependent insulinotropic action. Glucagon Suppression Coordinated GLP-1 and GIP activation suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production and supporting glycemic control. Gastric Emptying Slowing GLP-1 receptor activation slows gastric motility and nutrient absorption, reducing meal-stimulated glucose excursions and promoting sustained satiety. Central Appetite Suppression Both GLP-1 and GIP receptors activate hypothalamic appetite suppression pathways, providing synergistic reduction in hunger and food intake through overlapping neural mechanisms. Metabolic Optimization Dual activation of GLP-1 and GIP creates complementary metabolic effects—GLP-1 enhancing insulin secretion and gastric slowing while GIP modulates adipocyte metabolism and metabolic flexibility.
Preclinical Research Summary
Tirzepatide is supplied as sterile aqueous solution or lyophilized powder at concentrations of 1–10 mg/mL. Storage at 2–8°C; shelf-life 12–24 months for solutions, 24–36 months for lyophilized material. Analytical testing includes HPLC purity verification (≥95%), HPLC-MS molecular confirmation with dual agonist peptide structure verification, amino acid analysis, fatty acid acylation verification, and microbial sterility/endotoxin testing. Bioassay verification of dual receptor agonist activity available upon request. Certificate of Analysis provided with each lot.
Preclinical Research Summary
Tirzepatide is supplied as sterile aqueous solution or lyophilized powder at concentrations of 1–10 mg/mL. Storage at 2–8°C; shelf-life 12–24 months for solutions, 24–36 months for lyophilized material. Analytical testing includes HPLC purity verification (≥95%), HPLC-MS molecular confirmation with dual agonist peptide structure verification, amino acid analysis, fatty acid acylation verification, and microbial sterility/endotoxin testing. Bioassay verification of dual receptor agonist activity available upon request. Certificate of Analysis provided with each lot.
RUO Disclaimer
RESEARCH USE ONLY (RUO) This product is intended exclusively for laboratory research and is not approved for clinical use or human/animal administration. Not manufactured for pharmaceutical use. Users assume responsibility for suitability determination, proper storage, safety compliance, and regulatory adherence. Institutional approval (IACUC, IRB) may be required. Information provided is for research reference only and does not constitute medical advice or therapeutic claims.
RUO Disclaimer
RESEARCH USE ONLY (RUO) This product is intended exclusively for laboratory research and is not approved for clinical use or human/animal administration. Not manufactured for pharmaceutical use. Users assume responsibility for suitability determination, proper storage, safety compliance, and regulatory adherence. Institutional approval (IACUC, IRB) may be required. Information provided is for research reference only and does not constitute medical advice or therapeutic claims.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
© Standard BioLabs. All rights reserved.
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
© Standard BioLabs. All rights reserved.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
© Standard BioLabs. All rights reserved.
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.